MOTAWA E. EL-HOUSEINI1, MOSTAFA S. ARAFAT2, AHMED M. EL-HUSSEINY3, ISLAM M. KASEM2, MAHMOUD M. KAMEL4, AHMED H. EL-HABASHY5, MEDHAT M. KHAFAGY6, ENAS M. RADWAN4, MAHA H. HELAL7, MONA S. ABDELLATEIF1,*
Oncology Research, Vol.29, No.5, pp. 319-329, 2021, DOI:10.32604/or.2022.025249
- 10 October 2022
Abstract Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs (P = 0.001 and 0.017, respectively), similarly upregulation of… More >
Login
Register
